Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple disulfide-bonded states confer extensive conformational diversity in fibrinogen.

Protein science : a publication of the Protein Society·2026
Same author

Factor XII locking in (for contact activation through disulfide control).

Journal of thrombosis and haemostasis : JTH·2026
Same author

Drug Candidate BIO101 for Spinal Muscular Atrophy as Monotherapy or Combined With the Antisense Oligonucleotide ASO-10-27.

Journal of cachexia, sarcopenia and muscle·2025
Same author

Neuroprotective Effect of Mas Activation by BIO101 in Vincristine-Induced Small Fiber Neuropathy.

Journal of the peripheral nervous system : JPNS·2025
Same author

Extracellular PDI in thrombosis and vascular injury.

Thrombosis journal·2025
Same author

Disulfide bond control of platelet αIIbβ3 integrin.

Thrombosis research·2025

Related Experiment Video

Updated: Jul 13, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Arsenical-based cancer drugs.

Pierre J Dilda1, Philip J Hogg

  • 1UNSW Cancer Research Centre, University of New South Wales and Department of Haematology, Prince of Wales Hospital, Sydney 2052, Australia.

Cancer Treatment Reviews
|July 13, 2007
PubMed
Summary

Arsenic compounds, once abandoned for cancer treatment due to toxicity, are now re-emerging. Arsenic trioxide shows promise in treating acute promyelocytic leukemia and other cancers.

Area of Science:

  • Oncology
  • Toxicology
  • Medicinal Chemistry

Background:

  • Arsenic, a metalloid, exists in two main oxidation states: As(III) and As(V).
  • As(III) compounds exhibit cytotoxicity by reacting with protein thiols, forming stable cyclic dithioarsinite complexes.
  • Historically, arsenic compounds were used for various diseases, including leukemia, before modern therapies emerged.

Purpose of the Study:

  • To review past and present arsenical-based compounds for cancer treatment.
  • To discuss mechanisms of action, selectivity, and toxicity of these compounds.
  • To explore the future prospects of organoarsenicals in oncology.

Main Methods:

  • Literature review of historical and current uses of arsenic in cancer therapy.
  • Analysis of biochemical mechanisms underlying arsenic's cytotoxic effects.

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Related Experiment Videos

Last Updated: Jul 13, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

  • Evaluation of clinical data on arsenic trioxide and novel organoarsenicals.

    • Main Results:

    • Arsenic trioxide has demonstrated significant efficacy, inducing remissions in acute promyelocytic leukemia.
    • New classes of organoarsenicals are under investigation for hematological malignancies and solid tumors.
    • Understanding arsenic's cytotoxicity is crucial for developing safer, more effective cancer treatments.

    Conclusions:

    • Arsenical compounds are regaining attention in cancer therapy due to recent successes.
    • Further research into mechanisms and toxicity is essential for optimizing arsenical drug development.
    • Organoarsenicals represent a promising frontier in the treatment of various cancers.